Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal, MS
No cisgender woman who received injections of lenacapavir (LEN, Gilead) twice a year as pre-exposure prophylaxis (PrEP) became infected with HIV, according to an interim analysis of the PURPOSE 1 trial, reported at AIDS 2024, in Munich.
“UNAIDS reports that just over 3,000 young women of a similar age to those in PURPOSE 1 became newly infected with HIV every week in sub-Saharan Africa in